Dr. Zhongmin Ma is the founder and Chief Executive Officer of Revivallon Biopharmaceutical Co. Ltd and an Adjunct Investigator of Zhuhai Fudan Innovation Institute, Fudan University. Dr. Ma has dedicated his entire career to understanding the molecular mechanisms of pancreatic β-cell failure and regeneration and developing innovative drugs for the treatment of diabetes. He received his B.S. in Biology from Fudan University, China and his Ph.D. in Biochemistry from Saint Louis University School of Medicine, USA. Dr. Ma is an accomplished scientist and entrepreneur with nearly 30 years of experience in diabetes research and drug discovery. Prior to founding Revivallon, as an entrepreneur, he served 5 years as Vice President and Chief Scientific Officer at Diapin Therapeutics in the United States, developing innovative drugs for the treatment of metabolic diseases. Before joining Diapin, Dr. Ma was a professor at the Mount Sinai School of Medicine in New York, where his lab made significant breakthroughs in the regeneration of pancreatic β cells in vivo, laying the groundwork for the development of new drugs with potential to cure diabetes. In addition, he is one of the founders of the Chinese American Diabetes Association (CADA) and served as its president for one term.
Zhongmin Ma
